The amyloidoses are a group of deposition diseases in which the tissue deposits are composed of protein fibrils. These fibrils are the result of aggregation of specific precursor proteins into ordered structures which are resistant to proteolytic digestion and solubilisation. The ordered structure of the fibrils causes the deposits to be birefringent and, when histological sections are stained with Congo red, a characteristic green birefringence is seen by polarisation microscopy.
The amyloidoses can be classified into broad groups on the basis of distribution: (1) localised and (2) systemic (table 1). Both of these broad groups include hereditary and non-hereditary forms of deposition disease. Immunoglobulin (primary) amyloidosis is the most common form of non-hereditary systemic amyloidosis. In this disease the amyloid fibrils are composed of monoclonal immunoglobulin light chain molecules or degradation products of these light chains. Reactive (secondary) amyloidosis is usually seen in association with chronic inflammatory diseases. The amyloid fibrils in this disease contain a degradation product of the acute phase serum protein SAA. Amyloidosis associated with chronic haemodialysis has fibres synthesised from P2-microglobulin. While this type of amyloidosis is usually restricted to bones and joints, some systemic deposits may occur. The localised forms of non-hereditary amyloidosis include isolated amyloidosis of the genitourinary tract, isolated bronchopulmonary amyloidosis, lichen amyloidosis, most cases of Alzheimer's disease, the hyalinised islets of Langerhans in non-insulin dependent diabetes mellitus, and a number of others.
Familial amyloidotic polyneuropathy (FAP) associated with variants of plasma transthyretin (prealbumin) represents the most frequent form of inherited amyloidosis. ' In these syndromes the amyloid fibril deposits contain the variant trans- Anhidrosis can be a feature of FAP and, while not usually a clinically important feature, should be considered when patients are exposed to prolonged raised ambient temperatures.
The peripheral neuropathy of FAP-I often leads to foot ulcers which can give chronic cellulitis and osteomyelitis. When the sensory neuropathy progresses much more rapidly than the motor neuropathy, Charcot joint may occur, especially in the knee. Vitreous deposits of amyloid occur in several types of FAP-I and may be the initial presenting feature. Indeed, some patients may have loss of vision without symptoms of peripheral neuropathy. In the FAP-I Portuguese/Swedish syndrome (methionine 30 transthyretin), vitreous deposits are seen in patients who present at an older age.
FAP-I is usually associated with a variant form of plasma transthyretin (prealbumin). It is an autosomal dominant condition and most patients are heterozygous for the variant transthyretin. Patients homozygous for two different variants (methionine 30 and isoleucine 122) have been reported, but show no clinical features to distinguish them from their heterozygous fellow sufferers. There are now 10 single amino acid variants of plasma transthyretin that have been found to be associated with inherited amyloidosis. The majority of these are associated with neuropathy of the FAP type I. The classical description is the methionine 30 variant which was originally reported in patients in Northern Portugal, but has subsequently been found to be the cause of amyloidosis in Swedish, English, and Japanese families.2 It has also been described in Greece, Majorca, Cyprus, Turkey, and Brazil. The clinical features in patients with this mutation vary considerably from one family to another, but the peripheral neuropathy is usually ofthe FAP-I variety. The age ofpresentation can vary considerably. In Portuguese families the average age at onset is 32 or 33 years. In Sweden the average age of onset is 59 years. In the Portuguese patients progression of disease is over 10 to 15 years. Gastrointestinal, cardiac, and renal symptoms vary, but are the usual cause of death. In the Swedish population vitreous opacities are frequent.
The single patient with the isoleucine 33 transthyretin variant (Jewish) also had FAP-I. Severe gastrointestinal involvement was present. Onset of disease was in the late twenties and vitreous involvement was also a feature of the syndrome. The tyrosine 77 (Illinois/German) type of inherited amyloidosis is usually associated with an FAP-I neuropathy. The proband of the original kindred had renal involvement, but his family also had members who died with cardiac disease. A French kindred with tyrosine 77 transthyretin amyloidosis has predominantly cardiac disease associated with a typical FAP-I neuropathy.
FAP-I is not always associated with variants of transthyretin. The neuropathy in an Iowa kindred described by Van Allen et al3 in 1969 is typical of the type I variety. At that time, a high association of the syndrome with gastric ulcer led to a separate classification of FAP type III. Recently it has been shown that this syndrome is associated with a variant of apolipoprotein Al." No transthyretin abnormality has been found in this kindred and the apolipoprotein Al variant (arginine 26) has been shown to be associated with the syndrome over three generations. The amyloid deposits are composed of a truncated portion of the apolipoprotein Al molecule containing the variant arginine 26 residue. No normal apolipoprotein A1 was present in the amyloid deposits of the one patient that was studied in detail. Renal failure has been the usual cause of death although several patients had perforated gastric ulcers late in the clinical course. Vitreous deposits are not a feature of this disease.
A number of kindreds with typical FAP-I have been described in which variants of transthyretin have not yet been found. There have been reports that normal transthyretin can cause amyloidosis, but this has not been conclusively proven at the gene level.
Two recently described forms of hereditary amyloidosis associated with transthyretin variants would appear to belong in the category of FAP-I neuropathy. These include the asparagine 90 variant and the cysteine 114 variant of transthyretin.5 6 Both of these have a lower limb neuropathy. The Japanese patient with cysteine 114 was described as having significant autonomic involvement with decreased libido. Vitreous opacities were present in patients with both the asparagine 90 and cysteine 114 amyloidosis.
Familial amyloidotic polyneuropathy type II FAP type II was originally described in two separate kindreds of different origin: (1) a large Swiss family from Indiana and (2) Familial amyloidotic polyneuropathy without significant neuropathy There are a number of inherited amyloidoses associated with variants of transthyretin which do not show clinically significant degrees of peripheral neuropathy. The alanine 60 transthyretin amyloidosis usually presents as restrictive cardiomyopathy. Peripheral neuropathy is usually present, but not of a clinically significant degree. The carpal tunnel syndrome may occur later in the course of the disease. Autonomic involvement is a greater feature and may result in constipation, diarrhoea, gastric distension, impotence, and bladder retention. The onset of this syndrome is usually after the age of 50 and many patients live to 70 or 80 years before dying of restrictive cardiomyopathy. Gene carriers have been known to reach the age of 90 without significant disease.
The methionine 111 transthyretin variant causes the cardiac amyloidosis originally described by Frederiksen et al in 1962. At that time no neuropathy was reported and subsequent re-evaluation of patients in this kindred has not found evidence of peripheral The gene for gelsolin exists as a single copy on chromosome 9 . It codes for a circulating protein which has a mass of 93 000 daltons." Only a 9000 molecular weight fragment which must be from the middle of the molecule is deposited in the amyloid deposits of the Finnish type (FAP-IV). Gelsolin is an actin binding protein which may be involved in dissolution of actin. Two separate proteins, one intracellular and one extracellular with an additional 25 amino acid residues on the amino terminus, are the products of the same gene with different transcription start sites.
Proteins which are associated with localised forms of inherited amyloidosis include cystatin C, which is a protease inhibitor, and also the i protein ofAlzheimer's disease, which may also be a protease inhibitor. i protein is coded on chromosome 21 and only the carboxy terminal 42 amino acid residues are incorporated into amyloid fibrils.
Detection of gene carriers
The hereditary amyloidoses are an excellent example of molecular genetics in medicine. The use of molecular biology to identify genetic mutations which directly relate to clinical syndromes has made a basis for in depth studies on pathogenesis. In addition, the use of molecular biology techniques to identify gene carriers of the many different variant alleles has vastly expanded the scope of the clinical approach to these diseases.
The inherited amyloidoses are all delayed onset and autosomal dominant. The ability to detect gene carriers has not only been of value in genetic counselling and diagnosis, it has also allowed the recognition of inherited diseases which have less than complete penetrance or develop at a very advanced age. It has allowed analysis of differences in clinical syndromes in different ethnic groups where the identical mutation is found.
Since the complete genomic structure of the transthyretin gene is known, it has been relatively easy to develop methods to detect the various variant alleles. Most of the mutations in transthyretin that are associated with amyloidosis have resulted in changes in the restriction enzyme pattern of the transthyretin gene (table 3) . This originally allowed the development of tests for these genes using standard Southern analysis with radiolabelled probes. More recently, the development of enzymatic amplification of genomic 
